Extended Data Fig. 10: Subcutaneously implanted MASTER exhibited better control of tumor growth and extended survival compared under stressed dose conditions.
From: Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
A) Timeline of the study B) In vivo tumor bioluminescence imaging (BLI) of NSG mice (n = 6) treated with MASTER, conventional CAR-T cells, or control non-transduced (NT) cells. Mice were treated with 0.5 ×106 (left), 0.25 ×106 (middle), or 0.125 ×106 (right) CAR T cells. PBMCs seeded onto MASTER were normalized to transduction efficiency and both groups (MASTER and CAR T, i.v) were treated with equivalent number of CAR T cells. C-E) Survival of mice shown as Kaplan- Meier curves. **p < 0.01; ***p < 0.001 Log-rank (Mantel-Cox) test, Gehan-Breslow-Wilcoxon test.
